Número 3 - EII al día

protegerin but not receptor activator of NF-Kappa B ligand correlates withLarsen score in rheumatoid asthritis. Ann Rheum Dis 2004; 63: 216-7.56. Romas E, Gillespie Mt, Martin TJ. Involvement of receptor activator of NF-Kappa B ligand and tumor necrosis factor-alpha in bone destruction inrheumatoid asrthritis. Bone 2002; 30: 340-6.57. Norschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, WolfAM. The RANKL /OPG system is activated in inflammatory bowel diseaseand relates to the state of bone loss. Gut 2005; 54: 479-87.58. Ulivieri FM, Piodi LP, Taioli E, Lisciandrano D, Ranzi T, Vezzoli M, et al. Bonemineral density and body composition in ulcerative colitis: a six-year follow-up.Osteoporos Int 2001;12:343-8.59. Siffledeen JS, Fedorak RN, Siminoski K, Jen H, Vaudan E, Abraham N, etal. Bones and Crohn’s: risk factors associated with low bone mineral densityin patients with Crohn’s disease. Inflamm Bowel Dis 2004; 10: 220-228.60. Habtezion A, Silverberg MS, Parkes R, Mikolainis S, Steinhart AH. Risk factorsfor low bone density in Crohn’s disease. Inflamm Bowel Dis 2002; 8:87-92.61. Schulte C, Dignass AU, Mann K, Goebell H. Bone loss in patients with inflammatorybowel disease is less than expected: a follow-up study. ScandJ Gastroenterol 1999; 34: 696-702.62. Jahnsen J, Falch JA, Mowinckel P, Aadland E. Bone mineral density in patientswith inflammatory bowel disease: a population-based prospectivetwo-year follow-up study. Scand J Gastroenterol 2004; 39: 145-53.63. Bernstein CN, Seeger M, Sayre JW , Anton PA, Artinian L, Shanahan F. Decreasedbone density in inflammatory disease is related to corticoesteroiduse and not disease diagnosis. J Bone Miner Res 1995; 10: 250-6.64. Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C . Use of oralcorticosteroids and risk of fractures. J Bone Miner Res 2000; 15: 993-1000.65. Boot AM, Bouquet J, Krenning EP, de Muinck Keizer-Schrama SMPF. Bonemineral density and nutritional status in children with chronic inflammatorybowel disease. Am J Gastroenterol 1998; 93: 1483-90.66. Gokhale R, Favus MJ, Karrison T, Sutton MM, Rich B, Kirschner BS. Bonemineral density assesment in children with inflammatory bowel disease.Gastroenterology 1998; 114: 902-11.67. McCarthy D, Duggan P, O´Brien M, Kiely M, McCarthy J, Shanahan F, etal. Seasonality of vitamin D status and bone turnover in patients withCrohn´s disease. Aliment Pharmacol Ther 2005; 21: 1073-83.68. Vogelsang H, Ferenci P, Woloszczuk W. Bone disease in vitamin D-deficientpatients with Crohn´s disease. Gastroenterology 1982; 83: 1252-8.69. Silvennoinen J, Risteli L, Kattunen T, Risteli J. Increased degradation oftype I collagen in patients with inflammatory bowel disease. Gut 1996;38: 223-8.70. Odell, WD. Testosterone treatment of men treated with glucocorticoids(editorial). Arch Intern Med 1996; 156: 1133.71. D´Haens G, Verstraete K, Cheyns K et al. Bone turnover during short-termtherapy with metilprednisolone or budesonide in Crohn´s disease. AlimentPharmacolo Ther. 1998: 12: 410-24.72. Silvennoinen JA, Lethola JK, Niemela SE. Smoking is a risk factor for osteoporosisin women with inflammatory bowel disease. Scand J. Gastroenterol1996; 31: 367-71.73. Robinson RJ, Krzywicki T, Almond Lal-Azzawi F, Abrams K, Iqbal SJ, MayberryJF. Effect of a low-impact exercise program on bone mineral densityin Crohn´s disease: a randomized controlled trial. Gastroenterology 1988;115: 36-41.74. Thomas G.A. Rhodes J. Green J.T. Inflammatory Bowel Disease and Smoking—AReview. 1998; 93: 144-9 .75. Shea B, Wells G, Cranney A, Zytaruk N, Robinson V, Griffith L, et al. WITH-DRAWN: Calcium supplementation on bone loss in postmenopausal women.Cochrane Database Syst Rev 2007: CD004526.76. Papadimitropoulos E, Wells G, Shea B, Gillespie W, Weaver B, Zytaruk N,et al. Meta-analyses of therapies for postmenopausal osteoporosis. VIII:Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosisin postmenopausal women. Endocr Rev 2002; 23: 560-9.77. Gillespie WJ, Avenell A, Henry DA, O’Connell DL, Robertson J. Vitamin Dand vitamin D analogues for preventing fractures associated with involutionaland post-menopausal osteoporosis. Cochrane Database Syst Rev2001: CD000227.78. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE et al.Calcium plus vitamin D supplementation and the risk of fractures. N EnglJ Med 2006; 354: 669-83.79. Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W etal. A randomized, placebo- controlled trial of calcium supplementationfor decreased bone density in corticosteroid-using patients with inflammatorybowel disease: a pilot study. Aliment Pharmacol Ther 1996; 10:777-86.80. Boonen S, Rizzoli R, Meunier PJ, Stone M, Nuki G, Syversen U et al. Theneed for clinical guidance in the use of calcium and vitamin D in the managementof osteoporosis: a consensus report. Osteoporos Int 2004; 15:511-9.81. Menchén L, Ripoll C, Bretón I Moreno M, De la Cuerda C ,Camblor M. etal. Osteoporosis y enfermedad inflamatoria intestinal. Nutr Hosp 2005;20: 26-37.82. Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, HarrisS, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausalof osteoporotic fractures study. PROOF Study Group. Am J Med2000; 109: 267-276.83. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V et al.Metaanalysesof therapies for postmenopausal osteoporosis. II. Meta-analysisof alendronate for the treatment of postmenopausal women. Endocr Rev2002; 23: 508-16.84. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, etal. Meta-analyses of therapies for postmenopausal osteoporosis. III. Metaanalysisof risedronate for the treatment of postmenopausal osteoporosis.Endocr Rev 2002; 23: 517-23.85. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, etal.Treatment with once-weekly alendronate 70 mg compared with onceweekly risedronate 35 mg in women with postmenopausal osteoporosis:a randomized double-blind study. J Bone Miner Res 2005; 20: 141-51.86. Hosking D, Adami S, Felsenberg D, Andia JC, Valimaki M, Benhamou L,et al. Comparison of change in bone resorption and bone mineral densitywithonce-weekly alendronate and daily risedronate: a randomised,placebo-controlled study. Curr Med Res Opin 2003; 19: 383-94.87. Bonnick S, Saag KG, Kiel DP, McClung M, Hochberg M, Burnett SM, etal. Comparison of weekly treatment of postmenopausal osteoporosis withalendronate versus risedronate over two years. J Clin Endocrinol Metab2006; 91: 2631-7.88. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al.Alendronate for the prevention and treatment of glucocorticoid-inducedosteoporosis. Glucocorticoid-Induced Osteoporosis Intervention StudyGroup. N Engl J Med 1998; 339: 292-9.89. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, etal. Two-year effects of alendronate on bone mineral density and vertebralfracture in patients receiving glucocorticoids: a randomized, double-blind,placebo-controlled extension trial. Arthritis Rheum 2001; 44: 202-11.194 • Enfermedad Inflamatoria Intestinal al día - Vol. 7 - Nº. 2 - 2008